Exploring the changing landscape in Waldenström’s macroglobulinaemia: How will emerging BTK inhibitors alter patient outcomes?

This independent educational presentation was developed from the TouchTALK KOL Interview with Dr Tedeschi (ASPEN investigator), and covers the latest findings in second-generation BTK inhibitors for patients with WM.
Dr Tedeschi addresses three main topics about the use of BTK inhibitors in WM treatment, and provides data from the phase 3 ASPEN study and differentiation from Ibrutinib and Acalabrutinib. The main topics are as follows:
1.      Second-generation BTK inhibitors for patients with WM: What is the potential for improving outcomes?
2.      Maximizing outcomes for patients with WM: Adverse events associated with second-generation BTK inhibitors
3.      Using BTK inhibitors in clinical practice:  How is the landscape changing?

This TouchTALK presentation is an independent educational program developed by TouchOncology, supported by a BeiGene educational grant.